Signaling lymphocytic activation molecule F7 (SLAMF7), a molecule expressed on a subset of T cells, activated B cells, macrophage, and myeloma cells [3], is an attractive target to explore based on studies showing SLAMF7 expression in a subset of AITL cases [4]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.